INGESTIBLE FORMULATIONS FOR TRANSIENT, NONINVASIVE REDUCTION OF GASTRIC VOLUME

摘要

Provided are ingestible polymeric formulations and oral dosage forms for the reduction of gastric volume in the treatment of overweight and obese patients. The formulation includes an acid-sensitive, gelatin coating over a dehydrated hydrophilic polymer. When ingested, the acid-sensitive coating is quickly dissolved by gastric secretions and the hydrophilic polymer is exposed to the aqueous environment of the gastric milieu. The polymer absorbs water and expands to the point that will not allow the polymer to pass beyond the pyloric valve, and the expanded polymer is therefore trapped in the stomach.

主权项

1. A method of use of an oral dosage for drug delivery, comprising:
ingesting one or more ingestible tablets formed in a packed mass, the ingestible tablets comprising a biocompatible polymer in combination with a solubilizer/stabilization propylene glycol alginate agent which is adapted to maintain the polymer as a firm solid, wherein the polymer is adapted to (i) swell upon absorbing water from gastric, fluid to increase its size, thereby promoting its gastric retention, (ii) maintain it physical integrity in a stomach for at least 2 hours, and (iii) wherein the polymer includes one or more lipase-sensitive, fatty acid-like polymerizable groups or cross-linking groups such that the polymer is further degradable by an intestinal enzyme or exposure to an intestinal pH; maintaining a reduction of gastric volume within a stomach of the patient for at least 2 hours via the one or more ingestible tablets such that a sensation of fullness is induced in the patient without releasing a drug which induces the sensation; and disintegrating an acid-sensitive gelatin coating covering each of the one or more ingestible tablets within the stomach of the patient such that the one or more ingestible tablets disintegrate in the gastric fluid and disperse in the stomach at a first degradation rate; and further disintegrating the one or more ingestible tablets within an intestinal tract of the patient at a second degradation rate which is higher than the first degradation rate, and wherein the second degradation rate is sufficiently rapid to substantially prevent a small bowel obstruction by the polymer.